JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.
Skip to content
Characteristics
Secondary sensitivity analyses of a Phase 3b randomized trial
Peer reviewed
Population
Patients with treatment-resistant depression (TRD)
Intervention
Esketamine nasal spray
Topics
Esketamine
Key findings
Sensitivity analyses of the Phase 3b ESCAPE-TRD trial indicate that esketamine nasal spray was consistently more efficacious than extended-release quetiapine in patients with treatment-resistant depression, using multiple thresholds for remission and relapse. Specific effect sizes and numerical results are not reported in the text.
Abstract
Several sensitivity analyses of a Phase 3b trial have demonstrated that esketamine nasal spray was consistently more efficacious than extended‐release quetiapine in patients with treatment‐resistant depression (TRD). The additional analyses of the ESCAPE‐TRD trial used multiple thresholds for remission and relapse. Study results were published online Dec. 2, 2024, in The British Journal of Psychiatry.
Comparable studies
Other randomized controlled trials on
esketamine , most cited first.
Study
Year
Design
Participants
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
Adults with moderate to severe nonpsychotic depression and a history of nonresponse to...
2019
Phase 3, double-blind, active-controlled, multicenter randomized controlled trial
n = 227
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression
Adults with treatment-resistant depression who achieved stable remission or stable...
2019
Phase 3, multicenter, double-blind, randomized withdrawal study
n = 297
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression
Adults with DSM-IV-TR diagnosis of major depressive disorder and history of inadequate...
2017
Phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study
n = 67
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
Depressed patients at imminent risk for suicide
2018
Randomized controlled trial
n = 68
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
Adults with moderate-to-severe depression and nonresponse to at least two...
2019
Randomized controlled trial
n = 346
Create a free account to bookmark articles, vote on relevance, generate your own syntheses, and join the discussion.
For research and education, not medical advice. Talk with a clinician about your own care.
© 2026 The Consciousness Library
Support Our Mission
Choose your preferred way to support The Consciousness Library's work in advancing consciousness research.
A registered 501(c)(3) nonprofit; donations are tax-deductible in the US.
Donations are processed by Mindscape Collective, our legal entity, and may appear that way on your statement.